Novel integrase inhibitors for HIV

Expert Opinion on Investigational Drugs

Volumn 19, Issue 9, 2010, Pages 1087-1098

  Prada, Nicole ^a   Markowitz, Martin ^a  

^a AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

Elvitegravir; HIV 1; Integrase; Integrase inhibitor; LEDGF p75; Raltegravir; S GSK1265744; S GSK1349572

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GSK 1265744; GSK 1349572; INTEGRASE; INTEGRASE INHIBITOR; LAMIVUDINE; LENS EPITHELIUM DERIVED GROWTH FACTOR; RALTEGRAVIR; RITONAVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; REVIEW;

CELL LINE; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MALE; PYRROLIDINONES;

EID: 77955597658     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.501078     Document Type: Review

References (106)

1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998;352(9142):1725-1730
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853-860
3. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005;4(3):236-248
4. Wilkinson TA, Januszyk K, Phillips ML, et al. Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase. J Biol Chem 2009;284(12):7931-7939
5. Wu X, Liu H, Xiao H, et al. Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J Virol 1999;73(3):2126-2135
6. Zhu K, Dobard C, Chow SA. Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J Virol 2004;78(10):5045-5055
7. Dobard CW, Briones MS, Chow SA. Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription. J Virol 2007;81(18):10037-10046
8. Lu R, Ghory HZ, Engelman A. Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase. J Virol 2005;79(16):10356-10368 (Pubitemid 41098576)
9. Shun MC, Raghavendra NK, Vandegraaff N, et al. LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev 2007;21(14):1767-1778
10. Marshall HM, Ronen K, Berry C, et al. Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS One 2007;2(12):e1340
11. Deprez E, Tauc P, Leh H, et al. DNA binding induces dissociation of the multimeric form of HIV-1 integrase: a time-resolved fluorescence anisotropy study. Proc Natl Acad Sci USA 2001;98(18):10090-10095
12. Guiot E, Carayon K, Delelis O, et al. Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity. J Biol Chem 2006;281(32):22707-22719
13. Faure A, Calmels C, Desjobert C, et al. HIV-1 integrase crosslinked oligomers are active in vitro. Nucleic Acids Res 2005;33(3):977-986
14. Li M, Mizuuchi M, Burke TR Jr, et al. Retroviral DNA integration: reaction pathway and critical intermediates. EMBO J 2006;25(6):1295-1304
15. Brady T, Agosto LM, Malani N, et al. HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS 2009;23(12):1461-1471
16. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287(5453):646-650
17. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004;305(5683):528-532
18. Hare S, Gupta SS, Valkov E, et al. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010
19. Marchand C, Maddali K, Metifiot M, et al. HIV-1 IN inhibitors: 2010 update and perspectives. Curr Top Med Chem 2009;9(11):1016-1037
20. Ramkumar K, Serrao E, Odde S, et al. HIV-1 integrase inhibitors: 2007-2008 update. Med Res Rev 2010
21. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006;43(5):509-515
22. Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009;52(3):350-356
23. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;46(2):125-133
24. Gotuzzo E, Nguyen B-Y, Markowitz M, et al. Sustained Antiretroviral Efficacy of Raltegravir after 192 Weeks of Combination ART in Treatment-naive HIV-1-infected Patients [Poster 514]. 17th CROI; San Francisco, 16-19 February 2010
25. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374(9692):796-806
26. Lennox J, DeJesus E, Lazzarin A, et al. Raltegravir demonstrates durable efficacy through 96 weeks: results from STARTMRK, a phase III study of raltegravir (RAL)-based vs efavirenz (EFV)-based combination therapy in treatment-naive HIV-infected patients [Poster H924b]. 49th ICAAC; San Francisco, 12-15 September 2009
27. Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007;21(17):2315-2321
28. Sedaghat AR, Dinoso JB, Shen L, et al. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci USA 2008;105(12):4832-4837
29. Donahue D, Sloan R, Kuhl B, et al. Stage-dependent Inhibition of HIV-1 in vitro and Implications for Raltegravir [Poster 262]. 17th CROI; San Francisco, 16-19 February 2010
30. Sedaghat AR, Siliciano RF, Wilke CO. Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. Antivir Ther 2009;14(2):263-271
31. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007;369(9569):1261-1269
32. Gatell J, Katlama C, Grinsztejn B, et al. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II Study. J Acquir Immune Defic Syndr 2010;53(4):456-463
33. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359(4):339-354
34. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359(4):355-365
35. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010;50(4):605-612
36. Eron J, Cooper D, Steigbigel RT, et al. Sustained antiretroviral effect of raltegravir at week 156 in the BENCHMRK Studies and exploratory analysis of late outcomes based on early virologic responses [Poster 515]. 17th CROI; San Francisco, 16-19 February 2010
37. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375(9712):396-407
38. Harris M, Larsen G, Montaner JS. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS 2008;22(10):1224-1226
39. De Castro N, Braun J, Charreau I, et al. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis 2009;49(8):1259-1267
40. Scherrer AU, von Wyl V, Fux CA, et al. Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures. J Acquir Immune Defic Syndr 2010;53(4):464-471
41. Merck & Co., Inc.: ISENTRESS prescribing information. Available from: http://www.accessdata.fda.gov/drugsatf-da-docs/label/2009/022145s004lbl.pdf. [Date of access: 29 June 2010]
42. Charpentier C, Karmochkine M, Laureillard D, et al. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 2008;9(9):765-770
43. Fransen S, Gupta S, Danovich R, et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009;83(22):11440-11446
44. Fransen S, Karmochkine M, Huang W, et al. Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob Agents Chemother 2009;53(10):4522-4524
45. Malet I, Delelis O, Soulie C, et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 2009;63(4):795-804
46. da Silva D, Van Wesenbeeck L, Breilh D, et al. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 2010;65(6):1262-1269
47. Delelis O, Malet I, Na L, et al. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res 2009;37(4):1193-1201
48. Canducci F, Sampaolo M, Marinozzi MC, et al. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 2009;23(4):455-460
49. Ferns RB, Kirk S, Bennett J, et al. The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. AIDS 2009;23(16):2159-2164
50. Buzon MJ, Dalmau J, Puertas MC, et al. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. AIDS 2010;24(1):17-25
51. Croxtall JD, Lyseng-Williamson KA, Perry CM. Raltegravir. Drugs 2008;68(1):131-138
52. Croxtall JD, Keam SJ. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients. Drugs 2009;69(8):1059-1075
53. Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008;83(2):293-299
54. Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007;35(9):1657-1663
55. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009;53(7):2852-2856
56. A study to determine the safety and efficacy of once daily raltegravir compared to twice daily raltegravir. ClinicalTrials.gov identifier: NCT00745823. Available from: http://clinicaltrials.gov/ct2/show/NCT00745823? term=NCT00745823&rank=1
57. Marinello J, Marchand C, Mott BT, et al. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 2008;47(36):9345-9354
58. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008;82(2):764-774
59. Roquebert B, Damond F, Collin G, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008;62(5):914-920
60. Schafer JJ, Squires KE. Integrase inhibitors: a novel class of antiretroviral agents. Ann Pharmacother 2010;44(1):145-156
61. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006;43(1):1-5
62. Mathias AA, West S, Hui J, et al. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009;85(1):64-70
63. Ramanathan S, Kakuda TN, Mack R, et al. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. Antivir Ther 2008;13(8):1011-1017
64. Goethals O, Clayton R, Van Ginderen M, et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008;82(21):10366-10374
65. Garvey EP, Johns BA, Gartland MJ, et al. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother 2008;52(3):901-908
66. McColl DJ, Fransen S, Gupta S, et al. Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase 2 Study of elvitegravir (GS-9137) [Abstract 9]. XVI International Drug Resistance Workshop; Barbados, Bridgetown, 12-16 June 2007
67. Low A, Prada N, Topper M, et al. Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother 2009;53(10):4275-4282
68. Van Baelen K, Van Eygen V, Rondelez E, et al. Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS 2008;22(14):1877-1880
69. Zolopa AR, Berger DS, Lampiris H, et al. Activity of Elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 2010;201(6):814-822
70. Multicenter, randomized, double-blind, double-dummy, Phase 3 study of the safety and efficacy of ritonavir-boosted elvitegravir (EVG/r) versus raltegravir (RAL). ClinicalTrials.gov identifier: NCT00708162. Available from: http://clinicaltrials.gov/ct2/show/NCT00708162? term=elvitegravir&rank=4 Safety and efficacy of GS-9350-boosted atazanavir compared to ritonavir-boosted atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV-1 infected, antiretroviral treatment-naive adults
71. ClinicalTrials.gov identifier: NCT00892437. Available from: http://clinicaltrials.gov/ct2/show/NCT00892437?term= GS-9350&rank=1
72. Cohen C, Shamblaw D, Ruane P, et al. Single-tablet, fixed-dose regimen of elvitegravir/emtricitabine/tenofovir diso-proxil fumarate/GS-9350 achieves a high rate of virologic suppression and GS-9350 is an effective booster [Poster 58LB]. 17th CROI; San Francisco, 16-19 February 2010
73. Sato A, Kobayashi M, Yoshinaga T, et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor 5th IAS; Cape Town, 19-22 July 2009
74. Underwood M, Johns B, Sato A, et al. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy [Poster WePeA098]. 5th IAS; Cape Town, 19-22 July 2009
75. Seki T, Kobayashi M, Wakasa-Morimoto C, et al. S/GSK1349572 Is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones [Poster 555]. 17th CROI; San Francisco, 16-19 February 2010
76. Min S, Song I, Borland J, et al. Pharmacokinetic (PK) and safety in healthy subjects of S/GSK1349572, a next generation, once-daily HIV integrase inhibitor (INI). 5th IAS; Cape Town, 19-22 July 2009
77. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers [Poster A1-1303]. Antimicrob Agents Chemother; 54(1):254-258
78. Song I, Min S, Borland J, et al. Lack of interaction between the HIV integrase inhibitor, S/GSK1349572, and tenofovir disoproxil fumarate (TDF) in healthy subjects [Poster 616]. 49th ICAAC, 12-15 September 2009
79. Song I, Borland J, Chen S, et al. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next generation integrase inhibitor, S/GSK1349572. 17th CROI; San Francisco, 16-19 February 2010
80. Song I, Patel A, Min S, et al. Evaluation of antacid and multivitamin (MVI) effects on S/GSK1349572 pharmacokinetics (PK) in healthy subjects [Poster A1-1305]. 49th ICAAC; San Francisco, 12-15 September 2009
81. Lalezari J, Sloan L, DeJesus E, et al. Potent antiviral activity of S/GSK1349572, a next generation integrase inhibitor (INI), in INI-Naive HIV-1-infected patients: ING111521 protocol. 5th IAS. Cape Town, 19-22 July 2009. Abstract TUAB105
82. Song I, Chen S, Lou Y, et al. Pharmacokinetic (PK) and pharmacodynamic (PD) relationship of S/GSK1349572, a next generation integrase inhibitor (INI), in HIV-a infected patients [Poster WePeB250] 5th IAS; Cape Town; 19-22 July 2009
83. A dose ranging trial of GSK1349572 and 2 NRTI in HIV-1 infected, therapy naive subjects (ING112276). ClinicalTrials.gov identifier: NCT00951015. Available from: http://clinicaltrials.gov/ct2/show/NCT00951015
84. A clinical research study for assessing the effectiveness of the new integrase inhibitor GSK1349572 in HIV-infected persons with prior antiretroviral treatment and resistance to raltegravir. ClinicalTrials.gov identifier: NCT00950859. Available from http://clinicaltrials.gov/ct2/show/NCT00950859
85. Min S, DeJesus E, McCurdy L, et al. Pharmacokinetics (PK) and safety in healthy and HIV-infected subjects and short-term antiviral efficacy of S/GSK1265744, a next generation once daily HIV integrase inhibitor [Poster H-1228]. 49th ICAAC; San Francisco, 12-15 September 2009
86. Ceccherini-Silberstein F, Malet I, D'Arrigo R, et al. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009;11(1):17-29
87. Ge H, Si Y, Roeder RG. Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation. EMBO J 1998;17(22):6723-6729
88. Singh DP, Fatma N, Kimura A, et al. LEDGF binds to heat shock and stress-related element to activate the expression of stress-related genes. Biochem Biophys Res Commun 2001;283(4):943-955
89. Fatma N, Singh DP, Shinohara T, et al. Transcriptional regulation of the antioxidant protein 2 gene, a thiol-specific antioxidant, by lens epithelium-derived growth factor to protect cells from oxidative stress. J Biol Chem 2001;276(52):48899-48907
90. Maertens GN, Cherepanov P, Engelman A. Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin. J Cell Sci 2006;119(Pt 12):2563-2571
91. Ciuffi A, Llano M, Poeschla E, et al. A role for LEDGF/p75 in targeting HIV DNA integration. Nat Med 2005;11(12):1287-1289
92. Meehan AM, Saenz DT, Morrison JH, et al. LEDGF/p75 proteins with alternative chromatin tethers are functional HIV-1 cofactors. PLoS Pathog 2009;5(7):e1000522
93. Ronen K, Gijsbers R, Vets S, et al. Use of LEDGF/p75 Fusion proteins to retarget lentiviral integration outside of genes [Poster 145]. 17th CROI; San Francisco, 16-19 February 2010
94. Llano M, Saenz DT, Meehan A, et al. An essential role for LEDGF/p75 in HIV integration. Science 2006;314(5798):461-464
95. Vandekerckhove L, Christ F, Van Maele B, et al. Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. J Virol 2006;80(4):1886-1896
96. De Rijck J, Vandekerckhove L, Gijsbers R, et al. Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J Virol 2006;80(23):11498-11509
97. Llano M, Delgado S, Vanegas M, et al. Lens epithelium-derived growth factor/p75 prevents proteasomal degradation of HIV-1 integrase. J Biol Chem 2004;279(53):55570-55577
98. Sutherland HG, Newton K, Brownstein DG, et al. Disruption of Ledgf/Psip1 results in perinatal mortality and homeotic skeletal transformations. Mol Cell Biol 2006;26(19):7201-7210
99. Hombrouck A, De Rijck J, Hendrix J, et al. Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. PLoS Pathog 2007;3(3):e47
100. Benarous R, Barbey S, Simon A, et al. Identification of anti-retroviral compounds active on viruses resistant to raltegravir and that inhibit HIV-1 integration despite the absence of effect on the catalytic activity of integrase [Poster 555]. 16th CROI; Montreal, 8-11 February 2009
101. Debyser Z. Cellular co-factors of HIV integrase: from target identification to drug discovery. 16th CROI; Montreal, 8-11 February 2009
102. Christ F, Langedijk H, Bartholomeeussen K, et al. Novel treatment strategies in HIV-1 drug discovery: targeting the HIV-1 integrase-LEDGF/p75 interaction. 16th CROI; Montreal, 8-11 February 2009
103. De Luca L, Barreca ML, Ferro S, et al. Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. ChemMedChem 2009;4(8):1311-1316
104. Christ F, Voet A, Marchand A, et al. First-in-class inhibitors of LEDGF/p75-integrase interaction and HIV replication. 17th CROI; San Francisco, 16-19 February 2010
105. Christ F, Voet A, Marchand A, et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 2010;6(6):442-448
106. The DHHS Panel on antiretroviral guidelines for adults and adolescents-a Working Group of the Office of AIDS Research Advisory Council (OARAC): guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: http://aidsinfo.nih.gov/contentfiles/AdultandA- dolescentGL.pdf [Date of access: 29 June 2010]